Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAN2 Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.25 | -$0.24 | -$0.25 |
| Q2 2025 | 1 | -$0.24 | -$0.24 | -$0.24 |
| Q3 2025 | 1 | -$0.27 | -$0.27 | -$0.27 |
| Q4 2025 | 1 | -$0.26 | -$0.26 | -$0.26 |
| Q1 2026 | 1 | -$0.26 | -$0.26 | -$0.26 |
| Q2 2026 | 1 | -$0.27 | -$0.27 | -$0.27 |
| Q3 2026 | 1 | -$0.28 | -$0.28 | -$0.28 |
| Q4 2026 | 1 | -$0.28 | -$0.28 | -$0.28 |
AN2 Therapeutics, Inc. Earnings Date And Information
AN2 Therapeutics, Inc. last posted its earnings results on Wednesday, November 13th, 2024. The company reported $-0.43 earnings per share for the quarter, missing analysts' consensus estimates of $-0.37 by $0.06. The company had revenue of 0 for the quarter and had revenue of 0 for the year. AN2 Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.74 diluted earnings per share) and currently has a price-to-earnings ratio of -0.6. AN2 Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based on prior year's report dates.
AN2 Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$0.37 | -$0.43 | -0.06 | $0 | $0 |
| 08/13/2024 | Q2 2024 | -$0.63 | -$0.48 | 0.15 | $0 | $0 |
| 05/14/2024 | Q1 2024 | -$0.61 | -$0.56 | 0.05 | $0 | |
| 05/14/2024 | Q4 2023 | -$0.61 | -$0.57 | 0.04 | $80,000 | |
| 11/09/2023 | Q3 2023 | -$0.63 | -$0.65 | -0.02 | $0 | |
| 08/10/2023 | Q2 2023 | -$0.85 | -$0.81 | 0.04 | $0 | |
| 05/11/2023 | Q1 2023 | -$0.68 | -$0.75 | -0.07 | $0 | |
| 03/29/2023 | Q4 2022 | -$0.63 | -$0.66 | -0.03 | $0 | |
| 11/09/2022 | Q3 2022 | -$0.59 | -$0.56 | 0.03 | $0 | |
| 08/11/2022 | Q2 2022 | -$0.45 | -$0.50 | -0.05 | $0 | |
| 05/10/2022 | Q1 2022 | -$0.52 | -$0.40 | 0.12 | $0 | |
| 12/31/2021 | Q4 2021 | -$0.42 | $0 | |||
| 09/29/2021 | Q3 2021 | -$0.49 | $0 | |||
| 06/29/2021 | Q2 2021 | -$0.36 | $0 | |||
| 03/30/2021 | Q1 2021 | -$0.15 | $0 |
AN2 Therapeutics, Inc. Earnings: FAQ's
When is AN2 Therapeutics, Inc.'s earnings date?
AN2 Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based off last year's report dates.
How can I listen to AN2 Therapeutics, Inc.'s earnings conference
call?
The conference call for AN2 Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read AN2 Therapeutics, Inc.'s conference call transcript?
The conference call transcript for AN2 Therapeutics, Inc.'s latest earnings report can be read online.
How much profit does AN2 Therapeutics, Inc. generate each year?
AN2 Therapeutics, Inc. (:ANTX) has a recorded net income of $0. AN2 Therapeutics, Inc. has generated $-2.74 earnings per share over the last four quarters.
What is AN2 Therapeutics, Inc.'s price-to-earnings ratio?
AN2 Therapeutics, Inc. (:ANTX) has a price-to-earnings ratio of -0.6 and price/earnings-to-growth ratio is -0.06.